Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Stock Information for Relmada Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Relmada Therapeutics Inc.

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.